Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells.

ABSTRACT: Pancreatic cancer is characterized by mutated signaling pathways and a high incidence of drug resistance. Comprehensive, large-scale proteomic analysis can provide a system-wide view of signaling networks, assist in understanding drug mechanisms of action and interactions, and serve as a useful tool for pancreatic cancer research. In this study, liquid chromatography-mass spectrometry-based proteomic analysis was applied to characterize the combination of gemcitabine and birinapant in pancreatic cancer cells, which was shown previously to be synergistic. A total of 4069 drug-responsive proteins were identified and quantified in a time-series proteome analysis. This rich dataset provides broad views and accurate quantification of signaling pathways. Pathways relating to DNA damage response

SUBMITTER: Zhu X 

PROVIDER: S-EPMC5827530 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature